Precision Drilling
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Precision Drilling Corporation (PDS), founded in 1951 and headquartered in Calgary, Canada, specializes in providing land-based drilling, well completion, and production support services. The company ...
Latest News
3 days ago · globenewswire.com
PDS Biotech Reports Third Quarter 2026 Financial ResultsPRINCETON, N.J., Nov. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended September 30, 2026.
6 days ago · globenewswire.com
PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross ProceedsPRINCETON, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced NantWorks has exercised its outstanding common stock warrants to purchase an aggregate of 17,699,115 shares of the Company's common stock (or pre-funded warrants in lieu thereof) at an exercise price of $0.22 per share.
8 days ago · zacks.com
Is the Options Market Predicting a Spike in Precision Drilling Stock?Investors need to pay close attention to PDS stock based on the movements in the options market lately.
19 days ago · marketbeat.com
Precision Drilling Q3 Earnings Call HighlightsPrecision Drilling NYSE: PDS reported higher third-quarter revenue and a return to profitability as increased North American drilling activity and U.S. day rates offset weaker international results and elevated costs in the Middle East.
19 days ago · fool.com
Precision Drilling: 3 Key Takeaways for Long-Term InvestorsThird-quarter revenue increased 15% year over year to $532 million. Canadian contracted drilling rigs increased year over year from 16 to 28.
28 days ago · zacks.com
Wall Street Analysts Believe Precision Drilling (PDS) Could Rally 26.28%: Here's is How to TradeThe mean of analysts' price targets for Precision Drilling (PDS) points to a 26.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
28 days ago · globenewswire.com
PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of DirectorsJohn Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic Colorectal Cancer (mCRC) and PDS0101 toward potential partnerships John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic Colorectal Cancer (mCRC) and PDS0101 toward potential partnerships
1 month ago · zacks.com
Should Value Investors Buy Precision Drilling (PDS) Stock?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
1 month ago · marketbeat.com
PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal CancerPDS Biotechnology NASDAQ: PDSB outlined plans to advance its investigational immunocytokine PDS0301 into a Phase III study for heavily pretreated metastatic colorectal cancer with liver metastases, following discussions with the U.S. Food and Drug Administration and clinical findings from a National Cancer Institute-led study.
1 month ago · globenewswire.com
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver MetastasesPRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a virtual key opinion leader (KOL) event featuring Jonathan M.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove PDS